Open Nav

ivWatch, LLC

Recruit new investors for progressive steps to continually improve/validate product pipeline

  • Date:Thursday, October 18
  • Time:3:00 PM - 3:15 PM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:ivWatch develops and markets biomedical sensor technology products focused on infusion therapy and vascular access. Our market research has found that approximately 46 million IV placements annually are considered “high-risk” due to medication type and patient population, among other factors. Unlike continuous monitors available for heart rate/blood oxygen level, no technology has been available to continuously monitor an IV site and assess if drugs are being delivered to the vein without leakage. ivWatch has received multiple FDA clearances for a device that continuously monitors peripheral IVs for the early detection of infiltration/extravasation events, allowing for earlier intervention. Because of the prevalence of chronic diseases, the IV therapy device and injectable drug delivery markets’ growth projections support our current products and pipeline of new technologies. Regardless of delivery method, ivWatch stands ready to protect patients from harm from drug delivery errors.
  • Company Website:
  • Company HQ City:Hampton
  • Company HQ Country:United States
  • Company HQ State:Virginia                        
  • CEO/Top Company Official:Gary P. Warren, President and CEO
  • Year Founded:2010
  • Main Therapeutic Focus:Medical Devices
  • Lead Product in Development :ivWatch Model 400
  • Development Phase of Primary Product:Multiple Products in Market
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :One (OEM board)
  • Additional Information/Comments:Gary Warren was approached after a talk to review the original ivWatch device where he saw potential in the product. After the transfer of intellectual property to ivWatch, it was discovered the device had operational issues. Many would have folded at that point, but Gary was able to continue development through local angel investors. ivWatch was established in late 2010 and the company started staffing for growth. In early 2012, the company completed an out-of-house clinical trial at the Cincinnati Children's Hospital Medical Center and began internal validation studies to continue product development. The team has continued to achieve impressive milestones including: -FDA clearances for all patients -Innovative Technology contract from Vizient, Inc. -ISO 13485 Certification -Terumo Corporation named exclusive distributor for ivWatch in Japan -Breakthrough Technology contract from Premier Inc. -Philips Patient Monitor compatibility verification
  • Previous and Current Investors:Since NIH grants and transfer, company has been funded by local angel investors and family funds
  • Size of Last Investment Round:$14.8 million
  • Total Amount Raised to Date, In All Rounds:$36 million
Gary Warren
Scott Hensley
ivWatch, LLC